Editas Medicine Company

Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics.

Estimated Revenue: $1M to $10M
Funding Status: IPO
Headquarters: Cambridge, Massachusetts, United States
Total Funding: 656600000
Last Funding Date: 2021-01-21
Investors Number: 17
Founded Date: 2013-01-01
Industry: Atrificial Vectors and Immune Cells
Last Funding Type: Post-IPO Equity
Employee Number: 101-250